CARMAT |
Market Closed -
Other stock markets
|
After market 12:33:54 pm | |||
| 3.78 EUR | -2.45% |
|
3.79 | +0.26% |
| Mar. 25 | Carmat: final agreement with creditors | CF |
| Mar. 25 | Carmat Secures Two-year Extensions for Bank Loans | MT |
| Sales 2023 * | 8.1M 8.62M | Sales 2024 * | 25.94M 27.59M | Capitalization | 96.03M 102M |
|---|---|---|---|---|---|
| Net income 2023 * | -49M -52.13M | Net income 2024 * | -35M -37.24M | EV / Sales 2023 * | 18 x |
| Net Debt 2023 * | 49.63M 52.8M | Net Debt 2024 * | 78.97M 84.01M | EV / Sales 2024 * | 6.75 x |
| P/E ratio 2023 * |
-1.87
x | P/E ratio 2024 * |
-3.07
x | Employees | 177 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 85.45% |
More Fundamentals
* Assessed data
More news
Latest transcript on CARMAT
More press releases
More news
| 1 day | -3.48% | ||
| 1 week | -6.50% | ||
| Current month | -9.11% | ||
| 1 month | -2.22% | ||
| 3 months | -32.12% | ||
| 6 months | +2.47% | ||
| Current year | -44.18% |
1 week
3.72
4.00
1 month
3.684.40
Current year
3.667.72
1 year
3.009.99
3 years
3.0031.70
5 years
3.0036.00
10 years
3.0096.00
| Managers | Title | Age | Since |
|---|---|---|---|
Stéphane Piat
CEO | Chief Executive Officer | - | 16-08-31 |
Alain Carpentier
FOU | Founder | 91 | 08-06-24 |
| Director of Finance/CFO | - | 18-12-11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Alexandre Conroy
CHM | Chairman | 61 | 22-12-21 |
| Director/Board Member | 85 | 16-04-11 | |
Pierre Bastid
BRD | Director/Board Member | 69 | 18-04-04 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-16 | 3.78 | -2.45% | 41 074 |
| 24-04-15 | 3.875 | +0.26% | 13,662 |
| 24-04-12 | 3.865 | -0.39% | 23,707 |
| 24-04-11 | 3.88 | -1.52% | 18,954 |
| 24-04-10 | 3.94 | -1.50% | 34,806 |
Real-time Euronext Paris, April 16, 2024 at 09:07 am EDT
More quotes
CARMAT specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnostics system. The artificial heart is intended for patients with advanced cardiac insufficiency who are ineligible for a transplant and have exhausted all medication alternatives.
Calendar
2024-04-23
- Q4 2023 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
3.875
EUR
Average target price
14.22
EUR
Spread / Average Target
+266.97%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -44.18% | 102M | |
| +13.25% | 129B | |
| -10.69% | 10.41B | |
| +0.13% | 8.76B | |
| +9.69% | 6.76B | |
| +21.83% | 4.79B | |
| +8.20% | 3.43B | |
| +1.41% | 3.12B | |
| -13.00% | 2.04B | |
| -10.69% | 1.99B |
- Stock Market
- Equities
- ALCAR Stock
